“It literally saved my life. To live and be this well with no treatment more than three years after diagnosis is incredible,” she said. “I feel so lucky.
“I’m back at work full-time teaching. I’ve had no adverse effects. I’m super well and no one would know that I had cancer.”
Ms Moore, whose 37-year-old cousin died of melanoma in 2009, said she has not missed a day’s work at Burwood Girls High School due to illness since completing her treatment in October 2017.
The study suggests immunotherapy may work more effectively in patients with stage three melanoma when given before, rather than after surgery, because the bulky tumour can provoke an immune response. It found three quarters of patients in the trial responded well to dual immunotherapy given before surgery and only three per cent saw their tumours return after, suggesting 97 per cent could likely be cured.
The study’s senior author, Georgina Long, who is co-medical director at the Melanoma Institute Australia, said the treatment had flipped the “surgery then drugs rationale on its head”.
Professor Long said the neoadjuvant approach [drug therapy delivered before surgery] is a new way of dealing with melanoma and is a “game changer for stage three patients with bulky disease which has spread to their lymph nodes”.
“By utilising our arsenal of groundbreaking new treatments before surgical removal of the tumours, this approach is proving effective in stopping melanoma in its tracks and preventing its recurrence and spread to distant organs,” she said.
Professor Long said the therapy had also helped doctors make an early assessment on how well a patient was responding.
Cancer Australia chief executive officer Professor Dorothy Keefe said the report was “very interesting” and would encourage further trials of neoadjuvant therapy.
“Immunotherapy has dramatically improved outcomes for melanoma over the past few years and it seems further improvements are possible,” she said.
Melanoma Institute Australia oncologist Alex Menzies, the study co-author, said neoadjuvant therapy for stage three patients was not an approved standard of treatment.
“We anticipate that this will ultimately change following the very promising clinical trial results,” he said.
Australia has the highest melanoma rates in the world with one person diagnosed every 30 minutes and the Melanoma Institute Australia estimates 1300 people will die from the disease this year.
Anna Patty is a Senior Writer for The Sydney Morning Herald with a focus on higher education. She is a former Workplace Editor, Education Editor, State Political Reporter and Health Reporter.